Raul Sousa Freitas

Dr. Raul Sousa Freitas

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
LBLudmila Belayev
Ludmila Belayev
SHSung-Ha Hong
Sung-Ha Hong
HMHemant Menghani
Hemant Menghani
SMShawn J. Marcell
Shawn J. Marcell
AOAndre Obenaus
Andre Obenaus
NBNicolas G. Bazan
Nicolas G. Bazan

1 October 2016 in Journal of Periodontology
Verified
Journal Article
Closed access
LSLuzia Hermínia Sousa
Luzia Hermínia Sousa
ELEveline V. M. Linhares
Eveline V. M. Linhares
JAJoanna Trycia Alexandre
Joanna Trycia Alexandre
MLMario Roberto Lisboa
Mario Roberto Lisboa
FFFlavia Furlaneto
Flavia Furlaneto
PGPaula Goes
Paula Goes
Background: Atorvastatin (ATV) has shown pleiotropic effects on bone tissue, and osteoporosis can aggravate periodontitis. Thus, the effects of ATV on experimental periodontitis (EP) in rats subjected to glucocorticoid‐induced osteoporosis (GIOP) was assessed.Methods: Male Wistar rats were divided into the following groups: 1) naive; 2) EP; 3) GIOP + EP; and 4) ATV. Groups GIOP + EP and ATV received 7 mg/kg dexamethasone intramuscularly once per week for 5 weeks, and the others received saline (SAL). Groups EP, GIOP + EP, and ATV were submitted to EP by ligature around the maxillary left second molars for 11 days. Group ATV received 27 mg/kg ATV orally, and the others received SAL 30 minutes before EP. Periodontium was analyzed by macroscopy, microtomography, and histopathology; by immunohistochemical examination of receptor activator of nuclear factor‐κB ligand (RANKL), osteoprotegerin (OPG), wingless (WNT) 10b, dickkopf‐related protein 1 (DKK‐1), and β‐catenin; and by enzyme‐linked immunosorbent assay analysis of myeloperoxidase (MPO), tumor necrosis factor (TNF)‐α, interleukin (IL)‐1β, IL‐6, IL‐8, IL10, reduced glutathione (GSH), superoxide dismutase (SOD), and catalase (CAT). Leukogram, liver and kidney enzymes, and bone‐specific alkaline phosphatase (BALP) serum levels were evaluated.Results: ATV decreased bone loss, reduced MPO, TNF‐α, IL‐1β, IL‐6, and IL‐8, and increased IL‐10, GSH, SOD, and CAT levels. ATV reduced RANKL and DKK‐1 and increased OPG, WNT10b, and β‐catenin expressions and BALP activity.Conclusion: ATV reduced inflammation, oxidative stress, and bone loss in rats with EP and GIOP, with participation of the WNT signaling pathway.

5 August 2020 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Open access
PDF file
LBLudmila Belayev
Ludmila Belayev
SHSung‐Ha Hong
Sung‐Ha Hong
RFRaul Sousa Freitas
Raul Sousa Freitas
HMHemant Menghani
Hemant Menghani
SMShawn J. Marcell
Shawn J. Marcell
Nicolás BazánNicolás Bazán
Nicolás Bazán
Aims: Mesencephalic astrocyte‐derived neurotrophic factor (MANF) is a secretory neurotrophic factor protein that promotes repair after neuronal injury. The microglia cell surface receptor (triggering receptor expressed on myeloid cells‐2; TREM2) regulates the production of pro‐ and antiinflammatory mediators after stroke. Here, we study MANF and TREM2 expression after middle cerebral artery occlusion (MCAo) and explore if docosahexaenoic acid (DHA) treatment exerts a potentiating effect.Methods: We used 2 hours of the MCAo model in rats and intravenously administered DHA or vehicle at 3 hours after the onset of MCAo. Neurobehavioral assessment was performed on days 1, 3, 7, and 14; MANF and TREM2 expression was measured by immunohistochemistry and Western blotting.Results: MANF was upregulated in neurons and astrocytes on days 1, 7, and 14, and TREM2 was expressed on macrophages in the ischemic penumbra and dentate gyrus (DG) on days 7 and 14. DHA improved neurobehavioral recovery, attenuated infarct size on days 7 and 14, increased MANF and decreased TREM2 expression in ischemic core, penumbra, DG, and enhanced neurogenesis on Day 14.Conclusion: MANF and TREM2 protein abundance is robustly increased after MCAo, and DHA treatment potentiated MANF abundance, decreased TREM2 expression, improved neurobehavioral recovery, reduced infarction, and provided enhanced neuroprotection.

1 March 2017 in International Immunopharmacology
Verified
Journal Article
Closed access
IAIanna Wivianne Fernandes Araújo
Ianna Wivianne Fernandes Araújo
HCHellíada Vasconcelos Chaves
Hellíada Vasconcelos Chaves
JPJosé Mário Pachêco
José Mário Pachêco
DVDanielle Rocha Val
Danielle Rocha Val
LVLorena Vasconcelos Vieira
Lorena Vasconcelos Vieira
NBNorma M. B. Benevides
Norma M. B. Benevides

9 August 2019 in Current Pharmaceutical Design
Verified
Journal Article
Closed access
PDF file
IPIsabela Ribeiro Pinto
Isabela Ribeiro Pinto
HCHellíada V. Chaves
Hellíada V. Chaves
AVAuriana S. Vasconcelos
Auriana S. Vasconcelos
FSFrancisca Clea F de Sousa
Francisca Clea F de Sousa
TSTatiane Santi-Gadelha
Tatiane Santi-Gadelha
MBMirna Marques Bezerra
Mirna Marques Bezerra
Ethnopharmacological Relevance: Mucuna pruriens (Mp) belongs to Leguminosae family, it is native of tropical regions and used to treat several maladies such as urinary, neurological, and menstruation disorders, constipation, edema, fever, tuberculosis, ulcers, diabetes, arthritis, dysentery, and cardiovascular diseases. Mp seeds are rich in bioactive compounds, for instance, lectins, a heterogeneous group of proteins and glycoproteins with a potential role as therapeutic tools for several conditions, including gastric disorders. This study investigated the acute toxicity, gastroprotective, and antioxidant activities of a lectin from Mucuna pruriens seeds (MpLec) on ethanol-induced gastropathy model in mice.Materials & Methods: Mice received MpLec (5 or 10 mg/kg; i.v.) and were observed for acute toxicity signs; in another experimental series, mice were pre-treated with MpLec (0.001; 0.01 or 0.1 mg/kg, i.v.), ranitidine (80 mg/kg, p.o.), or saline (0.3 mL/30g, i.v.) before ethanol 99.9% (0.2 mL/animal, p.o.), and euthanized 30 min after ethanol challenge. Macroscopic and microscopic gastric aspects, biochemical parameters (tissue hemoglobin levels, iron-induced lipid peroxidation, GSH content, SOD activity, and gastric mucosal PGE2) were measured. Additionally, pharmacological tools (yohimbine, indomethacin, naloxone, L-NAME) were opportunely used to clarify MpLec gastroprotective mechanisms of action.Results: No toxicity signs nor death were observed at acute toxicity tests. MpLec reduced ethanol-induced gastric damage, edema, and hemorrhagic patches formation, as well as decreased lipid peroxidation, SOD activity, and increased GSH content. Yohimbine and indomethacin prevented MpLec effects, suggesting the involvement of alpha-2 adrenoceptors and prostaglandins in the MpLec-mediated effects.Conclusion: MpLec does not present toxicity signs and shows gastroprotective and antioxidant activities via alpha-2 adrenoceptors and prostaglandins in the ethanol-induced gastropathy model.

1 September 2016 in International Immunopharmacology
Verified
Journal Article
Closed access
RFRaul Sousa Freitas
Raul Sousa Freitas
DVDanielle Rocha Do Val
Danielle Rocha Do Val
MFMaria Ester Frota Fernandes
Maria Ester Frota Fernandes
FGFrancisco Isaac Fernandes Gomes
Francisco Isaac Fernandes Gomes
JLJosé Thalles Lacerda
José Thalles Lacerda
HCHellíada Vasconcelos Chaves
Hellíada Vasconcelos Chaves